Form 8-K - Current report:
SEC Accession No. 0001013762-25-002786
Filing Date
2025-03-26
Accepted
2025-03-26 17:00:27
Documents
14
Period of Report
2025-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0235681-8k_relmada.htm   iXBRL 8-K 37435
2 PRESS RELEASE ISSUED BY RELMADA THERAPEUTICS, INC. DATED MARCH 25, 2025 ea023568101ex99-1_relmada.htm EX-99.1 24868
  Complete submission text file 0001013762-25-002786.txt   247482

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE rlmd-20250324.xsd EX-101.SCH 3011
4 XBRL LABEL FILE rlmd-20250324_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE rlmd-20250324_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0235681-8k_relmada_htm.xml XML 3694
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 25774126
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)